Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HANA F SAFAH

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1447344783
CMS profile
156004
Location
BATON ROUGE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$299,993.95

258 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HANA F SAFAH

NPI 1447344783 · CMS profile ID 156004

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BATON ROUGE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447344783?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HANA F SAFAH, NPI 1447344783, CMS profile ID 156004. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447344783?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). HANA F SAFAH, NPI 1447344783, CMS profile ID 156004. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447344783?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
HANA F SAFAH, NPI 1447344783, CMS profile ID 156004, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1447344783?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

258 matching records · $299,993.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 258 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 258.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CTI BioPharma Corp. $900.0010/11/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965230149 CMS
Celgene Corporation $19.7510/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932808951 CMS
Incyte Corporation $4,920.0010/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015777 CMS
GlaxoSmithKline, LLC. $6.2510/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945093797 CMS
Incyte Corporation $4,920.0010/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015763 CMS
Incyte Corporation $195.0210/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015751 CMS
Incyte Corporation $4.0510/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015755 CMS
Incyte Corporation $10.6310/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015761 CMS
Incyte Corporation $55.0110/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015773 CMS
Incyte Corporation $13.7510/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015775 CMS
Incyte Corporation $10.0010/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015781 CMS
Kite Pharma, Inc. $25.0010/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920068131 CMS
Kite Pharma, Inc. $50.0010/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920068133 CMS
Kite Pharma, Inc. $61.3610/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920068135 CMS
Kite Pharma, Inc. $390.8009/30/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920068125 CMS
Kite Pharma, Inc. $418.0609/30/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920068127 CMS
Kite Pharma, Inc. $609.3509/30/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920068129 CMS
Incyte Corporation $522.2009/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015769 CMS
Incyte Corporation $360.0009/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015771 CMS
Incyte Corporation $200.0709/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015779 CMS
Blueprint Medicines Corporation $67.4509/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939275 CMS
Blueprint Medicines Corporation $3,731.0009/28/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939279 CMS
Blueprint Medicines Corporation $25.9409/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939285 CMS
Blueprint Medicines Corporation $20.6309/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939637 CMS
Blueprint Medicines Corporation $3,997.5009/28/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939641 CMS
Incyte Corporation $443.9609/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015753 CMS
Incyte Corporation $426.0109/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015757 CMS
Incyte Corporation $117.6509/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015759 CMS
GENZYME CORPORATION $1,075.2509/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938806075 CMS
GENZYME CORPORATION $5,103.0009/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938806077 CMS
GlaxoSmithKline, LLC. $4,800.0009/23/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945093793 CMS
Blueprint Medicines Corporation $28.7509/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939657 CMS
Blueprint Medicines Corporation $5,596.5009/21/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939661 CMS
Blueprint Medicines Corporation $38.9909/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939665 CMS
Blueprint Medicines Corporation $80.0009/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939289 CMS
Blueprint Medicines Corporation $350.9609/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939293 CMS
Blueprint Medicines Corporation $121.8609/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939645 CMS
Blueprint Medicines Corporation $108.6009/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939649 CMS
Blueprint Medicines Corporation $78.9809/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939653 CMS
Blueprint Medicines Corporation $241.3009/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939805 CMS
Blueprint Medicines Corporation $242.1509/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939809 CMS
Blueprint Medicines Corporation $301.5009/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939813 CMS
Blueprint Medicines Corporation $281.4009/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939817 CMS
Blueprint Medicines Corporation $80.0009/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939825 CMS
Blueprint Medicines Corporation $80.0009/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939669 CMS
Blueprint Medicines Corporation $108.6009/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939673 CMS
Blueprint Medicines Corporation $87.8609/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939677 CMS
Incyte Corporation $615.0009/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943015793 CMS
Blueprint Medicines Corporation $1,066.0008/31/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958939681 CMS
Genentech USA, Inc. $20.5808/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950700563 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $321,855.81 341
PY2020 $186,297.29 150
PY2021 $173,074.47 119
PY2022 $299,993.95 258
PY2023 $395,057.90 407
PY2024 $346,065.16 341
PY2025 $315,624.56 304

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $439,456.63 35
PY2024 Principal investigator $600,103.46 61
PY2023 Principal investigator $472,945.55 38
PY2022 Principal investigator $156,595.84 20
PY2021 Principal investigator $15,980.66 22
PY2020 Principal investigator $31,055.00 11
PY2019 Principal investigator $65,104.53 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $21,805.00 12/22/2025 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide No dispute reported 06/30/2026 1175400381
Principal investigator 1 ABBVIE INC. $12,098.70 12/04/2025 Covered Recipient Teaching Hospital
OUR LADY OF THE LAKE RMC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202418279
Principal investigator 1 PharmaEssentia USA Corporation $28,504.56 11/25/2025 Non-covered Recipient Entity
Tulane Cancer Center Clinical Trials Office
A22-301 No dispute reported 06/30/2026 1246829962
Principal investigator 1 PharmaEssentia USA Corporation $70,650.00 11/18/2025 Non-covered Recipient Entity
Tulane Cancer Center Clinical Trials Office
A22-203 No dispute reported 06/30/2026 1246829942
Principal investigator 1 ABBVIE INC. $3,792.15 11/05/2025 Covered Recipient Teaching Hospital
OUR LADY OF THE LAKE RMC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202418276
Principal investigator 1 Alexion Pharmaceuticals, Inc. $6,500.00 11/05/2025 Non-covered Recipient Entity
TULANE UNIVERSITY SCHOOL OF MEDICINE OFFICE OF ACADEMIC AFFAIRS
A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Cardiac Amyloidosis. No dispute reported 06/30/2026 1185540940
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,458.50 11/03/2025 Non-covered Recipient Entity
Tulane University Health Sciences Center
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235992847
Principal investigator 1 Alexion Pharmaceuticals, Inc. $6,500.00 10/16/2025 Non-covered Recipient Entity
TULANE UNIVERSITY SCHOOL OF MEDICINE OFFICE OF ACADEMIC AFFAIRS
A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients with Stage IIIb AL Cardiac Amyloidosis. No dispute reported 06/30/2026 1185540942
Principal investigator 1 ABBVIE INC. $27,606.15 10/09/2025 Covered Recipient Teaching Hospital
OUR LADY OF THE LAKE RMC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202418272
Principal investigator 1 ABBVIE INC. $18,805.00 09/29/2025 Covered Recipient Teaching Hospital
OUR LADY OF THE LAKE RMC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202418268
Principal investigator 1 PFIZER INC. $13,066.65 09/25/2025 Non-covered Recipient Entity
The Administrators of the Tulane Educational Fund
A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228829033
Principal investigator 1 PharmaEssentia USA Corporation $34,645.19 09/23/2025 Non-covered Recipient Entity
Tulane Cancer Center Clinical Trials Office
A22-301 No dispute reported 06/30/2026 1246829957
Principal investigator 1 PharmaEssentia USA Corporation $5,642.46 09/10/2025 Non-covered Recipient Entity
Tulane Cancer Center Clinical Trials Office
A22-203 No dispute reported 06/30/2026 1246829938
Principal investigator 1 PFIZER INC. $1,763.37 08/19/2025 Non-covered Recipient Entity
The Administrators of the Tulane Educational Fund
A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228827402
Principal investigator 1 PFIZER INC. $5,342.49 07/15/2025 Non-covered Recipient Entity
The Administrators of the Tulane Educational Fund
A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228830682
Principal investigator 1 PharmaEssentia USA Corporation $27,693.53 07/15/2025 Non-covered Recipient Entity
Tulane Cancer Center Clinical Trials Office
A22-301 No dispute reported 06/30/2026 1246829954
Principal investigator 1 ABBVIE INC. $2,700.00 07/09/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202497714
Principal investigator 1 Janssen Research & Development, LLC $24,660.00 06/30/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE ED UCATIONAL FUND DBA TULANE UNIVERSIT
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175400427
Principal investigator 1 PFIZER INC. $2,489.67 06/25/2025 Non-covered Recipient Entity
The Administrators of the Tulane Educational Fund
A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228830002
Principal investigator 1 Incyte Corporation $9,895.50 06/24/2025 Covered Recipient Teaching Hospital
Tulane Medical Center
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) No dispute reported 06/30/2026 1240489596
Principal investigator 1 PFIZER INC. $2,756.97 05/06/2025 Non-covered Recipient Entity
The Administrators of the Tulane Educational Fund
A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228832581
Principal investigator 1 PharmaEssentia USA Corporation $4,553.82 04/08/2025 Non-covered Recipient Entity
Tulane Cancer Center Clinical Trials Office
A22-203 No dispute reported 06/30/2026 1246829931
Principal investigator 1 PharmaEssentia USA Corporation $2,722.82 04/08/2025 Non-covered Recipient Entity
Tulane Cancer Center Clinical Trials Office
A22-203 No dispute reported 06/30/2026 1246829934
Principal investigator 1 PharmaEssentia USA Corporation $25,361.33 03/31/2025 Non-covered Recipient Entity
Tulane Cancer Center Clinical Trials Office
A22-301 No dispute reported 06/30/2026 1246829951
Principal investigator 1 PFIZER INC. $5,246.64 03/27/2025 Non-covered Recipient Entity
The Administrators of the Tulane Educational Fund
A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228833847
Principal investigator 1 PFIZER INC. $2,489.67 03/25/2025 Non-covered Recipient Entity
The Administrators of the Tulane Educational Fund
A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228833852
Principal investigator 1 PFIZER INC. $2,898.45 03/18/2025 Non-covered Recipient Entity
Tulane Cancer Center
AN OPENLABEL 3ARM MULTICENTER RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB PF06863135 MONOTHERAPY AND ELRANATAMAB DARATUMUMAB VERSUS DARATUMUMAB POMALIDOMIDE DEXAMETHASONE IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR No dispute reported 06/30/2026 1228833130
Principal investigator 1 PharmaEssentia USA Corporation $27,909.82 02/21/2025 Non-covered Recipient Entity
Tulane Cancer Center Clinical Trials Office
A22-301 No dispute reported 06/30/2026 1246829947
Principal investigator 1 PFIZER INC. $2,489.67 02/18/2025 Non-covered Recipient Entity
The Administrators of the Tulane Educational Fund
A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228828855
Principal investigator 1 PFIZER INC. $2,898.45 02/11/2025 Non-covered Recipient Entity
Tulane Cancer Center
AN OPENLABEL 3ARM MULTICENTER RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB PF06863135 MONOTHERAPY AND ELRANATAMAB DARATUMUMAB VERSUS DARATUMUMAB POMALIDOMIDE DEXAMETHASONE IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR No dispute reported 06/30/2026 1228829028
Principal investigator 1 PFIZER INC. $2,840.67 02/04/2025 Non-covered Recipient Entity
The Administrators of the Tulane Educational Fund
A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228829609
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,541.61 02/03/2025 Covered Recipient Teaching Hospital
TULANE MEDICAL CENTER
A RANDOMIZED, OPEN-LABEL, CONTROLLED, PHASE 2 STUDY OF PEVONEDISTAT, VENETOCLAX, AND AZACITIDINE VERSUS VENETOCLAX PLUS AZACITIDINE IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1223269824
Principal investigator 1 PFIZER INC. $2,898.45 01/21/2025 Non-covered Recipient Entity
Tulane Cancer Center
AN OPENLABEL 3ARM MULTICENTER RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB PF06863135 MONOTHERAPY AND ELRANATAMAB DARATUMUMAB VERSUS DARATUMUMAB POMALIDOMIDE DEXAMETHASONE IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR No dispute reported 06/30/2026 1228833651
Principal investigator 1 PFIZER INC. $4,979.34 01/21/2025 Non-covered Recipient Entity
The Administrators of the Tulane Educational Fund
A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228833658
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,250.00 01/03/2025 Non-covered Recipient Entity
Tulane Cancer Center
A Phase 1b, Open-Label, Dose-Finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of BMS-986158 Monotherapy and in Combination with Either Fedratinib or Ruxolitinib in Subjects with DIPSS-Intermediate or High Risk Myelofibrosis No dispute reported 06/30/2026 1235992855